AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
281.08B
Market cap281.08B
Price-Earnings ratio
27.37
Price-Earnings ratio27.37
Dividend yield
1.71%
Dividend yield1.71%
Average volume
2.34M
Average volume2.34M
High today
$181.96
High today$181.96
Low today
$180.00
Low today$180.00
Open price
$181.48
Open price$181.48
Volume
2.46M
Volume2.46M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$132.32
52 Week low$132.32

Stock Snapshot

As of today, AstraZeneca(AZN) shares are valued at $181.24. The company's market cap stands at 281.08B, with a P/E ratio of 27.37 and a dividend yield of 1.7%.

On 2026-05-05, AstraZeneca(AZN) stock moved within a range of $180.00 to $181.96. With shares now at $181.24, the stock is trading +0.7% above its intraday low and -0.4% below the session's peak.

Trading activity shows a volume of 2.46M, compared to an average daily volume of 2.34M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $132.32.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $132.32.

AZN News

TipRanks 2h
AstraZeneca Earnings Call: Oncology Strength, Pipeline Bets

AstraZeneca plc ((GB:AZN)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and p...

TipRanks 9h
AstraZeneca Advances Early Liver-Function Trial That Could Shape Dosing for Future AZN Drugs

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper de...

TipRanks 3d
AstraZeneca’s Calquence Gets Real World Safety Check in CLL Patients on Blood Thinners

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisio...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More AZN News

Nasdaq 4d
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong gu...

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat
TipRanks 4d
AstraZeneca Updates Total Voting Rights and Admits New Shares from Employee Schemes

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Benzinga 5d
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

FDA Panel Backs Truqap In Prostate Cancer The FDA panel voted 7-1, with one abstention, recognizing a favorable benefit-risk profile for AstraZeneca's Truqap (...

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters
The Wall Street Journal 5d
AstraZeneca’s Breast-Cancer Candidate Drug Loses FDA Panel Vote

The offices of AstraZeneca in England. The FDA isn’t bound by the committee’s vote, but its takes its advice into consideration. Paul Ellis / Agence France-Pres...

AstraZeneca’s Breast-Cancer Candidate Drug Loses FDA Panel Vote
TipRanks 5d
FDA panel’s negative vote clouds AstraZeneca’s bid for camizestrant in advanced breast cancer

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 5d
AstraZeneca says FDA AdCom recommend Truqap in mHSPC

The company states: “The US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recognised a favorable benefit risk profile for AstraZeneca’s...

TipRanks 5d
AstraZeneca: Buy Rating Reiterated as Camizestrant Upside and 18,000p Target Offset ODAC Setback

Jefferies analyst Michael Leuchten maintained a Buy rating on AstraZeneca today and set a price target of p18,000.00. Claim 55% Off TipRanks Unlock hedge fund-l...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.